BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

EnGene (NASDAQ: ENGN) stock suffered a more-than-80% plunge this past week that reflects just how competitive the field is among drug candidates for nonmuscle invasive bladder cancer (NMIBC)—and how ...

An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

Eli Lilly’s diabetes drug Mounjaro has become the world’s top-selling medication, surpassing Merck’s cancer therapy Keytruda. Lilly’s performance compounded when Mounjaro and weight-loss drug Zepbound ...

Major trial boost: Phase 2 data showed INBRX-106 plus Keytruda doubled response rates in high PD-L1 head and neck cancer patients. Deeper tumor shrinkage: Most responders in the combo arm had over 50% ...